Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
multivirus-specific T cell
- Development stage
- Preclinical
- Lead developer
- Acıbadem Labcell
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Multivirus-specific T cells (VSTs) are an adoptive cell therapy developed by Acıbadem Labcell for the treatment and prevention of multiple viral infections in immunocompromised patients, particularly those who have undergone hematopoietic stem cell transplantation (HSCT). This therapy involves the ex vivo expansion of donor-derived or patient-derived T cells that are primed to recognize specific antigens from several common opportunistic viruses, typically including Cytomegalovirus (CMV), Epstein-Barr virus (EBV), Adenovirus (AdV), BK virus (BKV), and Human Herpesvirus 6 (HHV-6). By infusing these specialized T cells, the patient's immune system is bolstered with a population of effector cells capable of identifying and eliminating virus-infected cells, thereby controlling viral replication and preventing the development of severe clinical diseases such as CMV retinitis, EBV-associated post-transplant lymphoproliferative disorder (PTLD), or hemorrhagic cystitis.
- Other names
- Multivirüs Spesifik T HücreMultivirus-Specific T Cell
02
Targets
pp65/HLA-A*02:01 (CMV pp65 peptide-HLA-A*02:01 complex)pMHC (Peptide-MHC complex family)Human herpesvirus 6-derived peptides presented by Human Leukocyte Antigen class I/IIBK polyomavirus peptide-HLA complexesHAdV (Human adenovirus)JC polyomavirus homologous peptide-HLA complexes
Beyond the preview
Go deeper on multivirus-specific T cell.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on multivirus-specific T cell.